



Eris Lifesciences said that it has formed a joint venture with MJ Biopharm of Mumbai to enter the insulin market.

Eris MJ Biopharm, a 70:30 joint venture with Eris owning 70% of the company, would primarily market and distribute human and analogue insulin, such as Aspart, Glargine, and Lispro, as well as GLP-1 agonists and possibly additional biopharma drugs in India. MJ will be in charge of the JV's product development, manufacture, and distribution.

Site Moved. Visit our New Website

We have moved this news site from this URL

to <https://www.newprojectstracker.com/capex-news> .

Visit this site for regular updates

Buy Latest Research Reports